Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Role of Altered CD40-Ligand Gene Transcription in Systemic Lupus Erythematosus

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified December 2003 by National Center for Research Resources (NCRR).
Recruitment status was:  Recruiting
Sponsor:
Collaborator:
Arthritis Foundation
Information provided by:
National Center for Research Resources (NCRR)
ClinicalTrials.gov Identifier:
NCT00008749
First received: January 16, 2001
Last updated: June 23, 2005
Last verified: December 2003
  Purpose
Systemic lupus erythematosus is an often devastating autoimmune disease which affects 1 in 2,000 women in the United States. Recently, several research laboratories have reported that a protein, named CD40-ligand (CD154), is overexpressed by a subset of white blood cells, called lymphocytes, in patients with lupus. Expression of CD154 appears critical to the generation of antibodies that cause disease in lupus. Blocking CD154 interactions in the immune system has been shown to decrease disease activity in animal models of lupus. We propose to study the regulation of CD154 in patients with lupus in hopes of inhibiting its abnormal and deleterious expression.

Condition
Lupus Erythematosus, Systemic

Study Type: Observational
Study Design: Observational Model: Case Control
Observational Model: Natural History
Official Title: Role of Altered CD40-Ligand Gene Transcription in Systemic Lupus Erythematosus

Resource links provided by NLM:


Further study details as provided by National Center for Research Resources (NCRR):

  Eligibility

Ages Eligible for Study:   13 Years and older   (Child, Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion:

A diagnosis of systemic lupus erythematosus

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00008749

Locations
United States, Pennsylvania
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States, 19104-4318
Sponsors and Collaborators
National Center for Research Resources (NCRR)
Arthritis Foundation
  More Information

ClinicalTrials.gov Identifier: NCT00008749     History of Changes
Other Study ID Numbers: NCRR-M01RR00240-1736 
Study First Received: January 16, 2001
Last Updated: June 23, 2005
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Lupus Erythematosus, Systemic
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases

ClinicalTrials.gov processed this record on December 08, 2016